|
NCCN Flash Update sent March 25, 2013
NCCN has published updates for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (ALL). These NCCN Guidelines® are currently available as Version 1.2013.
- Ph-negative ALL (ALL-5 and ALL-6)
- For
consolidation options in AYA patients and Adults (age > 65 years),
factors to consider for allogeneic HSCT modified to include poor-risk
cytogenetics and to remove WBC counts (except as a footnote for the
latter).
- Relapsed/Refractory ALL (ALL-7)
- The treatment recommendations for AYA and Adult patients consolidated.
- The
following footnote added for allogeneic HSCT: For patients relapsing
after allogeneic HSCT, a second allogeneic HSCT and/or donor lymphocyte
infusion (DLI) can be considered.
- Donor lymphocyte infusion (DLI) removed as a treatment option for Ph+ ALL (except as a footnote, as mentioned above).
- Supportive Care (ALL-B)
- Prophylactic anti-infectives (ALL-B 1 of 4)
- The
following added: VZV prophylaxis (eg, acyclovir) for at least 1 year
after HSCT in transplant patients; and HBV prophylaxis (eg, adefovir,
entecavir, lamivudine) for at least 6-12 months after HSCT depending on
HBV serology.
- Steroid management (ALL-B 1 of 4)
- The following added: Consider dose reduction for steroid-induced psychosis and mood alteration.
- Asparaginase Toxicity Management (ALL-B 3 of 4)
- Toxicity grade clarified as CTCAE.
- Toxicity grades changed from 2, 3, 4 to 1, 2, 3-4.
- Systemic allergic reaction/anaphylaxis: recommendations for dosing substitutions removed.
- Pancreatitis;
Grade 1 and 2 recommendations combined: Continue asparaginase for
asymptomatic amylase or lipase elevation >3.0 x ULN (chemical
pancreatitis) or only radiologic abnormalities; observe closely for
rising amylase or lipase levels. Continue pegaspargase for
nonsymptomatic chemical pancreatitis but observe patient closely for
development of symptomatic pancreatitis for early treatment. Grade 3 and
4 recommendations combined: Permanently discontinue all asparaginase
for clinical pancreatitis (vomiting, severe abdominal pain) with amylase
or lipase elevation >3 x ULN for >3 days and/or development of
pancreatic pseudocyst.
- Asparaginase Toxicity Management (ALL-B 4 of 4)
- Non-CNS hemorrhage; Grade 2 to 4
recommendations combined: For bleeding in conjunction with
hypofibrinogenemia, withhold asparaginase until bleeding £ grade 1, until acute toxicity and clinical signs resolve, and coagulant replacement therapy stable or completed.
- CNS hemorrhage; Grade 1 and 2
recommendations combined: Discontinue all asparaginase; if CNS symptoms
and signs are fully resolved and significant asparaginase remains to be
administered, may resume asparaginase therapy at a lower dose and/or
longer intervals between doses.
- CNS thrombosis; Grade 2 recommendation modified with the addition of “with closely monitored anticoagulation.”
- Evaluation and Treatment of Extramedullary Involvement (ALL-C)
- CNS leukemia clarified as having CNS-3 and/or cranial nerve involvement.
- Principles of Chemotherapy (ALL-D)
- Induction regimens for Ph-positive ALL (ALL-D 1 of 4)
- Adult patients aged ³40 years; the following treatment option added: TKIs + vincristine + dexamethasone.
- Protocols for AYA patients aged 15-39 years; the following treatment options added:
TKIs + hyper-CVAD: imatinib or
dasatinib; and hyper-fractionated cyclophosphamide, vincristine,
doxorubicin, and dexamethasone, alternating with high-dose methotrexate,
and cytarabine.
TKIs + multiagent chemotherapy:
imatinib; and daunorubicin, vincristine, prednisone, and
cyclophosphamide.
- Maintenance regimens (ALL-D 1 of 4)
- Modified to: Monthly
vincristine/prednisone pulses (for 2-3 years). May include weekly
methotrexate + daily mercaptopurine (6-MP) as tolerated. The following
footnote added: May be necessary to reduce dose/eliminate antimetabolite
in the setting of myelosuppression and/or hepatotoxicity.
- Salvage regimens for relapsed/refractory ALL (ALL-D 3 of 4)
- Ph-positive ALL; Ponatinib added as a treatment option.
- Treatment Options Based on BCR-ABL Kinase Domain Mutation Status (ALL-G)
- This table was updated to include Ponatinib.
- The Discussion section was updated to reflect all changes within the algorithm.
For the complete updated versions of the NCCN Guidelines, the NCCN Drugs and Biologics Compendium (NCCN Compendium®), and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.com.
|
